Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

13. března 2020 aktualizováno: University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

Přehled studie

Postavení

Neznámý

Detailní popis

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

Typ studie

Intervenční

Zápis (Očekávaný)

50

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Clermont-Ferrand, Francie, 63000
        • CHU de Clermont-Ferrand

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

12 let až 16 let (Dítě)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Prevence
  • Přidělení: Nerandomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Žádný zásah: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
cardiac ectopic fat deposits
Časové okno: Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
Časové okno: Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
Časové okno: Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
Časové okno: Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
Časové okno: Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
Časové okno: Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
Časové okno: Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
Časové okno: Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
Časové okno: Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
Časové okno: Day 0
left myocardial regional function (MRI)
Day 0

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
macrovascularisation
Časové okno: Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
Časové okno: Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
Časové okno: Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
Časové okno: Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
Časové okno: Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
Časové okno: Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
Časové okno: Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
Časové okno: Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
Časové okno: Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
Časové okno: Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
Časové okno: Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
Časové okno: Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
Časové okno: Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
Časové okno: Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
Časové okno: Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
Časové okno: Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
Časové okno: Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
Časové okno: Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
Časové okno: month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
Časové okno: Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
Časové okno: Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
Časové okno: Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
Časové okno: Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
Časové okno: Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
Časové okno: Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
Časové okno: month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
Časové okno: Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
Časové okno: Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
Časové okno: Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
Časové okno: Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
Časové okno: Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
Časové okno: Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
Časové okno: Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
Časové okno: Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
Časové okno: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
Časové okno: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
Časové okno: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
Časové okno: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
Časové okno: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
Časové okno: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
Časové okno: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
Časové okno: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
Časové okno: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
Časové okno: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
Časové okno: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
Časové okno: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
Časové okno: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
Časové okno: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
Časové okno: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
Časové okno: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
Časové okno: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
Časové okno: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
Časové okno: Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
Časové okno: Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
Časové okno: Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
Časové okno: Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
Časové okno: Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
Časové okno: Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
Časové okno: day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
Časové okno: Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
Časové okno: Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
Časové okno: Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
Časové okno: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
Časové okno: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
Časové okno: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
Časové okno: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
Časové okno: Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
Časové okno: Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
Časové okno: Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
Časové okno: Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
Časové okno: Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
Časové okno: Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
Časové okno: Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
Časové okno: Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
Časové okno: Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
Časové okno: Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
Časové okno: Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
Časové okno: Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
Časové okno: Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
Časové okno: Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
Časové okno: Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
Časové okno: Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
Časové okno: Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
Časové okno: Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
Časové okno: Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
Časové okno: Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
Časové okno: Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
Časové okno: Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
Časové okno: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
Časové okno: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
Časové okno: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
Časové okno: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
Časové okno: Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
Časové okno: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
Časové okno: day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
Časové okno: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
Časové okno: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
Časové okno: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
Časové okno: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
Časové okno: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
Časové okno: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
Časové okno: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
Časové okno: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
Časové okno: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Časové okno: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Časové okno: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
Časové okno: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
Časové okno: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
Časové okno: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
Časové okno: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
Časové okno: day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
Časové okno: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
Časové okno: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
Časové okno: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
Časové okno: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
Časové okno: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
Časové okno: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
Časové okno: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
Časové okno: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
Časové okno: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
Časové okno: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
Časové okno: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
Časové okno: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
Časové okno: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
Časové okno: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
Časové okno: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
Časové okno: Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
Časové okno: Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
Časové okno: Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
Časové okno: Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
Časové okno: Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
Časové okno: Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
Časové okno: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
Časové okno: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
Časové okno: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
Časové okno: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
Časové okno: Day 0
measure of weight in kilograms
Day 0
weight
Časové okno: Month 3
measure of weight in kilograms
Month 3
waist circumference
Časové okno: Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
Časové okno: Month 3
measure of waist circumference in centimetres
Month 3

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Očekávaný)

1. září 2020

Primární dokončení (Očekávaný)

1. června 2021

Dokončení studie (Očekávaný)

1. června 2021

Termíny zápisu do studia

První předloženo

10. února 2020

První předloženo, které splnilo kritéria kontroly kvality

13. března 2020

První zveřejněno (Aktuální)

17. března 2020

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

17. března 2020

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

13. března 2020

Naposledy ověřeno

1. února 2020

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (Jiný identifikátor: ANSM)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

Nerozhodný

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na 3-month lifestyle intervention

3
Předplatit